II 

112TH CONGRESS 

2D SESSION S. 3189 

To amend the Controlled Substances Act to place synthetic drugs in Schedule 

I. 

IN THE SENATE OF THE UNITED STATES 

MAY 16, 2012 

Mr. PORTMAN introduced the following bill; which was read twice and referred 

to the Committee on the Judiciary 

A BILL 

To amend the Controlled Substances Act to place synthetic 

drugs in Schedule I. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. SHORT TITLE. 

4 This Act may be cited as the ‘‘Synthetic Drug Con5 trol Act of 2012’’. 

6 SEC. 2. ADDITION OF SYNTHETIC DRUGS TO SCHEDULE I 

7 OF THE CONTROLLED SUBSTANCES ACT. 

8 (a) CANNABIMIMETIC AGENTS.—Schedule I, as set 

9 forth in section 202(c) of the Controlled Substances Act 


jbell on DSK7SPTVN1PROD with BILLS
2 

•S 3189 IS

1 (21 U.S.C. 812(c)) is amended by adding at the end the 

2 following: 

3 ‘‘(d)(1) Unless specifically exempted or unless listed 

4 in another schedule, any material, compound, mixture, or 

5 preparation which contains any quantity of 

6 cannabimimetic agents, or which contains their salts, iso7 mers, and salts of isomers whenever the existence of such 

8 salts, isomers, and salts of isomers is possible within the 

9 specific chemical designation. 

10 ‘‘(2) In paragraph (1): 

11 ‘‘(A) The term ‘cannabimimetic agents’ means 

12 any substance that is a cannabinoid receptor type 1 

13 (CB1 receptor) agonist as demonstrated by binding 

14 studies and functional assays within any of the fol15 lowing structural classes: 

16 ‘‘(i) 2-(3-hydroxycyclohexyl)phenol with 

17 substitution at the 5-position of the phenolic 

18 ring by alkyl or alkenyl, whether or not sub19 stituted on the cyclohexyl ring to any extent. 

20 ‘‘(ii) 3-(1-naphthoyl)indole or 3-(1- 

21 naphthylmethane)indole by substitution at the 

22 nitrogen atom of the indole ring, whether or not 

23 further substituted on the indole ring to any ex24 tent, whether or not substituted on the naph25 thoyl or naphthyl ring to any extent. 


jbell on DSK7SPTVN1PROD with BILLS
3 

•S 3189 IS

1 ‘‘(iii) 3-(1-naphthoyl)pyrrole by substi2 tution at the nitrogen atom of the pyrrole ring, 

3 whether or not further substituted in the 

4 pyrrole ring to any extent, whether or not sub5 stituted on the naphthoyl ring to any extent. 

6 ‘‘(iv) 1-(1-naphthylmethylene)indene by 

7 substitution of the 3-position of the indene ring, 

8 whether or not further substituted in the indene 

9 ring to any extent, whether or not substituted 

10 on the naphthyl ring to any extent. 

11 ‘‘(v) 3-phenylacetylindole or 3- 

12 benzoylindole by substitution at the nitrogen 

13 atom of the indole ring, whether or not further 

14 substituted in the indole ring to any extent, 

15 whether or not substituted on the phenyl ring 

16 to any extent. 

17 ‘‘(B) Such term includes— 

18 ‘‘(i) 5-(1,1-dimethylheptyl)-2-[(1R,3S)-3- 

19 hydroxycyclohexyl]-phenol (CP–47,497); 

20 ‘‘(ii) 5-(1,1-dimethyloctyl)-2-[(1R,3S)-3- 

21 hydroxycyclohexyl]-phenol (cannabicyclohexanol 

22 or CP–47,497 C8-homolog); 

23 ‘‘(iii) 1-pentyl-3-(1-naphthoyl)indole 

24 (JWH–018 and AM678); 


jbell on DSK7SPTVN1PROD with BILLS
4 

•S 3189 IS

1 ‘‘(iv) 1-butyl-3-(1-naphthoyl)indole (JWH– 

2 073); 

3 ‘‘(v) 1-hexyl-3-(1-naphthoyl)indole (JWH– 

4 019); 

5 ‘‘(vi) 1-[2-(4-morpholinyl)ethyl]-3-(1-naph6 thoyl)indole (JWH–200); 

7 ‘‘(vii) 1-pentyl-3-(2- 

8 methoxyphenylacetyl)indole (JWH–250); 

9 ‘‘(viii) 1-pentyl-3-[1-(4- 

10 methoxynaphthoyl)]indole (JWH–081); 

11 ‘‘(ix) 1-pentyl-3-(4-methyl-1-naph12 thoyl)indole (JWH–122); 

13 ‘‘(x) 1-pentyl-3-(4-chloro-1-naph14 thoyl)indole (JWH–398); 

15 ‘‘(xi) 1-(5-fluoropentyl)-3-(1-naph16 thoyl)indole (AM2201); 

17 ‘‘(xii) 1-(5-fluoropentyl)-3-(2- 

18 iodobenzoyl)indole (AM694); 

19 ‘‘(xiii) 1-pentyl-3-[(4-methoxy)-ben20 zoyl]indole (SR–19 and RCS–4); 

21 ‘‘(xiv) 1-cyclohexylethyl-3-(2- 

22 methoxyphenylacetyl)indole (SR–18 and RCS– 

23 8); and 

24 ‘‘(xv) 1-pentyl-3-(2- 

25 chlorophenylacetyl)indole (JWH–203).’’. 


jbell on DSK7SPTVN1PROD with BILLS
5 

•S 3189 IS

1 (b) OTHER DRUGS.—Schedule I of section 202(c) of 

2 the Controlled Substances Act (21 U.S.C. 812(c)) is 

3 amended in subsection (c) by adding at the end the fol4 lowing: 

5 ‘‘(18) 4-methylmethcathinone (Mephedrone). 

6 ‘‘(19) 3,4-methylenedioxypyrovalerone (MDPV). 

7 ‘‘(20) 3,4-methylenedioxymethcathinone 

8 (methylone). 

9 ‘‘(21) Naphthylpyrovalerone (naphyrone). 

10 ‘‘(22) 4-fluoromethcathinone (flephedrone). 

11 ‘‘(23) 4-methoxymethcathinone (methedrone; 

12 Bk–PMMA). 

13 ‘‘(24) Ethcathinone (N-Ethylcathinone). 

14 ‘‘(25) 3,4-methylenedioxyethcathinone 

15 (ethylone). 

16 ‘‘(26) Beta-keto-N-methyl-3,4- 

17 benzodioxyolybutanamine (butylone). 

18 ‘‘(27) N,N-dimethylcathinone 

19 (metamfepramone). 

20 ‘‘(28) Alpha-pyrrolidinopropiophenone (alpha21 PPP). 

22 ‘‘(29) 4-methoxy-alpha23 pyrrolidinopropiophenone (MOPPP). 

24 ‘‘(30) 3,4-methylenedioxy25 alphapyrrolidinopropiophenone (MDPPP). 


jbell on DSK7SPTVN1PROD with BILLS
6 

•S 3189 IS

1 ‘‘(31) Alpha-pyrrolidinovalerophenone (alpha2 PVP). 

3 ‘‘(32) 6,7-dihydro-5H-indeno-(5,6-d)-1,3-dioxol4 6-amine) (MDAI). 

5 ‘‘(33) 3-fluoromethcathinone. 

6 ‘‘(34) 4’-Methyl-α-pyrrolidinobutiophenone 

7 (MPBP). 

8 ‘‘(35) 2-(2,5-Dimethoxy-4- 

9 ethylphenyl)ethanamine (2C–E). 

10 ‘‘(36) 2-(2,5-Dimethoxy-4- 

11 methylphenyl)ethanamine (2C–D). 

12 ‘‘(37) 2-(4-Chloro-2,5- 

13 dimethoxyphenyl)ethanamine (2C–C). 

14 ‘‘(38) 2-(4-Iodo-2,5- 

15 dimethoxyphenyl)ethanamine (2C–I). 

16 ‘‘(39) 2-[4-(Ethylthio)-2,5- 

17 dimethoxyphenyl]ethanamine (2C–T–2). 

18 ‘‘(40) 2-[4-(Isopropylthio)-2,5- 

19 dimethoxyphenyl]ethanamine (2C–T–4). 

20 ‘‘(41) 2-(2,5-Dimethoxyphenyl)ethanamine (2C– 

21 H). 

22 ‘‘(42) 2-(2,5-Dimethoxy-4-nitro23 phenyl)ethanamine (2C–N). 

24 ‘‘(43) 2-(2,5-Dimethoxy-4-(n)- 

25 propylphenyl)ethanamine (2C–P).’’. 


jbell on DSK7SPTVN1PROD with BILLS
7 

•S 3189 IS

1 SEC. 3. TEMPORARY SCHEDULING TO AVOID IMMINENT 

2 HAZARDS TO PUBLIC SAFETY EXPANSION. 

3 Section 201(h)(2) of the Controlled Substances Act 

4 (21 U.S.C. 811(h)(2)) is amended— 

5 (1) by striking ‘‘one year’’ and inserting ‘‘2 

6 years’’; and 

7 (2) by striking ‘‘six months’’ and inserting ‘‘1 

8 year’’. 

Æ 


jbell on DSK7SPTVN1PROD with BILLS